{
Regeneron Pharmaceuticals, Inc.

Companies

}
Symbol REGN
Name Regeneron Pharmaceuticals, Inc.
Currency USD
Sector Health Care
IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
Industry Biotechnology
Market NASDAQ Global Select
Country United States
State NY
City Tarrytown
Zipcode 10591-6707
Website http://www.regeneron.com
Track all markets on TradingView
Intellia Therapeutics stock plummets amid disappointing therapy data and performance
Intellia Therapeutics, Inc. has seen its shares plummet 60.4% in 2024, significantly underperforming the industry and the S&P 500. Despite promising data from its CRISPR-based therapies, including the investigational nexiguran ziclumeran for ATTR amyloidosis, investor disappointment has grown due to recent trial results. The company continues to advance its innovative gene editing pipeline, with ongoing studies showing substantial serum TTR reduction in patients.
Yahoo Finance
Regeneron Pharmaceuticals, Inc. Intellia Therapeutics, Inc. USA
Healthcare, Market Report
18:57 20.12.2024
global uveitis treatment market poised for significant growth by 2032
The Global Uveitis Treatment market is projected to grow from USD 725 million in 2024 to USD 1.28 billion by 2032, with a CAGR of 8.5%. The study covers various treatment types, including corticosteroids and biologic agents, and offers customization options for regional and application-specific analysis. Key players include Novartis, Pfizer, and AbbVie, with North America leading the market and Asia-Pacific identified as the fastest-growing region.
openPR.com
Pfizer Inc. Bayer AG Novartis AG Regeneron Pharmaceuticals, Inc. Merck & Co., Inc. CIPLA LTD Lupin Limited Hoffmann-La Roche AG Bausch Health Companies Inc. BIOGEN ABBVIE Alimera Sciences Inc. SAU ISR FRA RUS DEU TWN ARG ARE AUT TUR SGP NZL CHL USA BRA CAN ITA JPN IDN GBR ESP IND MYS COL AUS THA EGY VNM KOR PHL CHN ZAF MEX Nidhi Bhavsar Show more
Healthcare, Market Report
20:41 19.12.2024
Regeneron advances Eylea HD for retinal vein occlusion amid rising competition
Regeneron's Eylea HD has demonstrated noninferior visual acuity gains compared to the original Eylea in patients with macular edema following retinal vein occlusion, paving the way for a 2025 FDA filing. The drug, which generated $392 million in U.S. sales in Q3, faces competition from Amgen's biosimilar and Roche's Vabysmo, but its potential approval in RVO could boost sales further.
Fierce Pharma
United States Dollar Bayer AG Regeneron Pharmaceuticals, Inc. Hoffmann-La Roche AG Amgen Inc. USA George Yancopoulos Show more
Healthcare, Market Report
14:20 18.12.2024
Roche secures EU approval for Vabysmo prefilled syringe for retinal diseases
Roche has received EU approval for a prefilled syringe (PFS) of its ophthalmology drug Vabysmo, designed to treat neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion. This PFS offers a convenient administration method for over 9 million affected individuals in the EU and is the first of its kind containing a bispecific antibody for these conditions. Following strong sales growth, the approval is expected to further enhance Roche's revenue amid increasing competition in the ophthalmology market.
Yahoo Finance
Swiss Franc Bristol-Myers Squibb Co Regeneron Pharmaceuticals, Inc. Hoffmann-La Roche AG Gilead Sciences, Inc. CHE Show more
Healthcare, Market Report
19:40 16.12.2024
Roche gains EU approval for Vabysmo prefilled syringe to challenge Eylea
Roche has received EU approval for its Vabysmo prefilled syringe, targeting three retinal conditions that lead to blindness: wet age-related macular degeneration, diabetic macular oedema, and macular oedema following retinal vein occlusion. This ready-to-use formulation complements the existing vial option and aims to challenge Regeneron's Eylea, which currently dominates the market. With Vabysmo's sales surging 324% to $2.64bn, forecasts suggest it could reach $8.78bn by 2030, while Eylea's sales are expected to decline significantly.
Yahoo Finance
Euro Regeneron Pharmaceuticals, Inc. Hoffmann-La Roche AG DEU CHE Levi Garraway
Healthcare, Market Report
13:19 13.12.2024
Xaira Therapeutics appoints former Roche executive as chief medical officer
Xaira Therapeutics has appointed former Roche executive Paulo Fontoura as its Chief Medical Officer, enhancing its leadership team amid a wave of retirements at companies like Alnylam and Regeneron. The billion-dollar AI-focused startup continues to expand its C-suite.
Endpoints News
Regeneron Pharmaceuticals, Inc. Hoffmann-La Roche AG CHE Paulo Fontoura
Technology & Innovation, News Article
13:00 13.12.2024
healthcare innovation portfolio targets advancements in pharmaceuticals and medical technologies
The convergence of science and technology is transforming healthcare, with Syfe's Healthcare Innovation portfolio offering diversified investment across genomics, biotechnology, pharmaceuticals, healthcare services, and medical devices. This portfolio includes six carefully selected ETFs, providing exposure to leading companies and innovations in the sector, while managing risks associated with long-term healthcare investments. With no minimum investment and low fees, it aims to capitalize on the future of healthcare advancements.
Connect
Masimo Corporation Vertex Pharmaceuticals Incorporated Abbott Laboratories GE HealthCare Technologies Inc. AtriCure, Inc. Regeneron Pharmaceuticals, Inc. Intuitive Surgical, Inc. CRISPR Therapeutics AG Veeva Systems Inc. Johnson & Johnson Cigna Integra LifeSciences Holdings Corporation CVS Health Corporation Stryker Corporation UnitedHealth Group Incorporated Amgen Inc. Penumbra, Inc. Alphatec Holdings, Inc. UCB SA Boston Scientific Corporation Eli Lilly and Company USA BEL Beigene Revolution Medicines Gilead Sciences Exelixis Incyte Show more
Finance & Economy, Market Report
02:52 13.11.2024
global healthcare services market poised for significant growth through 2028
The global healthcare services market is projected to grow from $8,348.44 billion in 2023 to $8,963.64 billion in 2024, driven by advancements in medical technology, an aging population, and health insurance expansion. By 2028, it is expected to reach $10,908.99 billion, with key trends including telemedicine integration and patient-centered care. Shared medical appointments are gaining traction as a cost-effective model for managing chronic conditions, enhancing patient outcomes through collaborative care.
openPR.com
United States Dollar Community Health Systems, Inc. UnitedHealth Group Incorporated CVS Health Corporation Regeneron Pharmaceuticals, Inc. Cardinal Health, Inc. Fresenius Medical Care AG & Co. KGaA Centene Corporation Baxter International Inc. Mayo Clinic Agilent Technologies, Inc. Johnson & Johnson Pfizer Inc. Cleveland Clinic Global Solutions LLC McKesson Corporation Merck & Co., Inc. Abbott Laboratories Bristol-Myers Squibb Company Quest Diagnostics Incorporated HCA Healthcare, Inc. Gilead Sciences, Inc. Kaiser Permanente Group Trust Cigna Corporation Stryker Corporation Tenet Healthcare Corporation Danaher Corporation AbbVie Inc. Boston Scientific Corporation Molina Healthcare, Inc. Align Technology, Inc. AmerisourceBergen Corporation Laboratory Corporation OF America Holdings DaVita Inc. Eli Lilly and Company Humana Inc. West Pharmaceutical Services, Inc. Fresenius Medical Care AG & Co. KGaA Kaiser Permanente UnitedHealth Group Incorporated Tenet Healthcare HCA Healthcare Show more
Healthcare, Market Report
20:40 11.11.2024
Regeneron Pharmaceuticals receives buy rating amid strong sales and collaborations
Regeneron Pharmaceuticals, Inc. has received a buy rating from UBS, highlighting its focus on developing treatments for eye diseases, inflammatory conditions, and cancer. The company's net sales are primarily derived from product sales (56.6%) and collaboration agreements (40.4%), with significant partnerships with Sanofi, Bayer, and Roche. As of the end of 2022, Regeneron boasts a clinical development portfolio of approximately 35 products.
MarketScreener
United States Dollar Bayer AG Sanofi Hoffmann-La Roche AG Regeneron Pharmaceuticals, Inc. DEU FRA USA Roche Bayer Sanofi Show more
TradFi, Market Report
16:08 01.11.2024
regeneron pharmaceuticals receives buy rating as it expands drug portfolio
Regeneron Pharmaceuticals, Inc. has received a buy rating from UBS, highlighting its focus on developing treatments for eye diseases, inflammatory conditions, and cancer. The company's net sales are primarily derived from product sales (56.6%) and collaboration agreements (40.4%), with significant partnerships with Sanofi, Bayer, and Roche. As of the end of 2022, Regeneron boasts a clinical development portfolio of approximately 35 products.
ch.marketscreener.com
United States Dollar Bayer AG Sanofi Hoffmann-La Roche AG Regeneron Pharmaceuticals, Inc. DEU FRA USA Roche Bayer Sanofi Show more
TradFi, Market Report
16:08 01.11.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Cryptocurrency Trends Market Sentiment Analysis Central Bank Actions Banking Regulations Corporate Responsibility & ESG Decentralized Finance (DeFi) Innovations Tokenomics and Crypto Economics Mergers & Acquisitions Cryptocurrency & Blockchain Regulations Cryptocurrency Developments Blockchain Technology Adoption Anti-Money Laundering (AML) Regulations Market Analysis and Predictions Emerging Startups Cryptocurrency Regulations Inflation Rates & CPI Data SEC & Financial Compliance Banking & Investment Regulations
Countries:
USA CHE GBR DEU ARE HKG AUS JPN CHN IND SGP DNK CAN NGA FIN COL AUT VGB LIE TUR
Companies:
Credit Suisse Real Estate Fund Siat BlackRock, Inc. Coinbase Global, Inc. Solana USD Ethereum USD Ripples USD Apple Inc. Tesla, Inc. Fidelity Contrafund Cardano USD NVIDIA Corporation Grayscale Litecoin Trust Chainlink USD Tether USDt CNY Google Inc. Amazon.com, Inc. MicroStrategy Inc Franklin Templeton - Franklin M End Federal Reserve USD MicroStrategy Incorporated
Currencies:
United States Dollar Euro Swiss Franc Japanese Yen Australian Dollar Indian Rupee Canadian Dollar Mozambican Metical British Pound Sterling Norwegian Krone Mongolian Tögrög Colombian Peso Singapore Dollar
People:
Donald Trump Ali Martinez Elon Musk Karin Keller-Sutter Jerome Powell Ueli Maurer Michael J. Saylor Thomas Jordan Gary Gensler Colm Kelleher Alan Santana Paul Atkins Joe Rogan Martin Schlegel Isabelle Chassot Mario Nawfal Paolo Ardoino Sergio Ermotti Dana White Joe Biden

MachinaCore is a highly modular and scalable system that allows users to build custom widgets and tools tailored to their specific financial data needs, while seamlessly integrating with other MachinaLabs products, like Machinary, MachinaAI Modules and MachinaTrader.

Links

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.